Meeting Highlights

The Advanced Practice Perspective


Search by:   

    SOHO 2021 Annual Meeting

    Alexis C. Geppner, MLS, CTTS, PA-C, on ALL and Hyper C-VAD: Lessons Learned and New Approaches



    Watch Video

    Alexis C. Geppner, MLS, CTTS, PA-C, of The University of Texas MD Anderson Cancer Center, discusses key data that advanced practitioners need to know about treatment for patients with acute lymphocytic leukemia, the shift away from intensive chemotherapy with the use of monoclonal antibodies and tyrosine kinase inhibitors, and whether overall responses and survival can be maintained or improved.

    SOHO 2021 Annual Meeting

    Alexis C. Geppner, MLS, CTTS, PA-C, on IDH-Mutated AML: Beyond Enasidenib and Ivosidenib Monotherapy



    Watch Video

    Alexis C. Geppner, MLS, CTTS, PA-C, of The University of Texas MD Anderson Cancer Center, discusses important updates that advanced practitioners need to be aware of when treating patients with acute myeloid leukemia, including two key driver mutations (IDH1 and IDH2), the inhibitors ivosidenib and enasidenib, lower-intensity chemotherapy combinations, and the role of venetoclax and azacitidine.

    SOHO 2021 Annual Meeting

    Alexis C. Geppner, MLS, CTTS, PA-C, on Targeting p53 in MDS



    Watch Video

    Alexis C. Geppner, MLS, CTTS, PA-C, of The University of Texas MD Anderson Cancer Center, discusses key information for advanced practitioners on the impact of TP53 mutations on prognosis in myelodysplastic syndrome, the implications of serial TP53 analyses, and novel therapeutic strategies for treating patients with TP53-mutant disease.

    SOHO 2021 Annual Meeting

    Lisa Nodzon, PhD, ARNP, AOCNP, on Myelofibrosis: New Therapeutic Approaches



    Watch Video

    Lisa Nodzon, PhD, ARNP, AOCNP, of the H. Lee Moffitt Cancer Center & Research Institute, discusses potential new treatment strategies for patients with myelofibrosis that advanced practitioners should be aware of, including anemia therapy in combination with a JAK inhibitor, first-line combination treatments, new second-line therapies, and strategies for patients with very low platelets.

    SOHO 2021 Annual Meeting

    Lisa Nodzon, PhD, ARNP, AOCNP, on Richter Syndrome: Therapeutic Strategies



    Watch Video

    Lisa Nodzon, PhD, ARNP, AOCNP, of the H. Lee Moffitt Cancer Center & Research Institute, discusses an update on treating Richter Syndrome, including information on clonally related vs unrelated variants of the disease; the role of venetoclax, acalabrutinib, pirtobrutinib, and DA-EPOCH-VR chemotherapy; and the use of immune checkpoint inhibitors and CAR T-cell therapy; as well as a number of ongoing clinical trials on combinations of various targeted agents.

    SOHO 2021 Annual Meeting

    Lisa Nodzon, PhD, ARNP, AOCNP, on BCMA-Directed CAR-T Cells: Early Results and Future Directions



    Watch Video

    Lisa Nodzon, PhD, ARNP, AOCNP, of the H. Lee Moffitt Cancer Center & Research Institute, discusses key information for advanced practitioners on the B-cell maturation antigen, a target for multiple myeloma, and CAR T-cell therapy, now approved for relapsed or refractory disease. Although the results have been encouraging, relapses still occur, highlighting the need to understand how best to sequence the regimen and the role of antibody-drug conjugates, bispecific antibodies, and CAR-T cells.

    SOHO 2021 Annual Meeting

    Kelly Valla, PharmD, BCOP, on T-Cell Lymphoma: Immunotherapy Approaches



    Watch Video

    Kelly Valla, PharmD, BCOP, of Winship Cancer Institute of Emory University, discusses updates on CAR T-cell therapy and what advanced practitioners need to be aware of when treating patients with rare lymphomas: how best to sequence these agents; the potential acute and long-term toxicities; available clinical trials; and appropriate referral to centers, especially for those who may not have many viable treatment options.

    SOHO 2021 Annual Meeting

    Kelly Valla, PharmD, BCOP, on Aggressive B-Cell Lymphoma: The Next Wave of Novel Agents



    Watch Video

    Kelly Valla, PharmD, BCOP, of Winship Cancer Institute of Emory University, discusses important data that advanced practitioners need to know about bispecific antibodies in the pipeline such as mosunetuzumab, glofitamab, and epcoritamab and how they may fit into the treatment paradigm; new antibody-drug conjugates; and how to sequence the agents, manage their toxicities, and deliver supportive care.

    SOHO 2021 Annual Meeting

    Kelly Valla, PharmD, BCOP, on Relapsed/Refractory MCL: Novel Treatment Approaches



    Watch Video

    Kelly Valla, PharmD, BCOP, of Winship Cancer Institute of Emory University, discusses mantle cell lymphoma and what advanced practitioners should know about improving outcomes in relapsed and refractory disease with BTK inhibitors such as treatment with pirobrutinib; other new agents such as parsaclisib, a PI3K delta inhibitor, and the bispecific agent epcoritamab; and CAR T-cell therapy. She also relays some clinical pearls on toxicity management (including financial toxicity) and supportive care.

     

    2020 ASH Annual Meeting

    Beth Faiman, PhD, MSN, APRN-BC, AOCN, FAAN, on Daratumumab, Pomalidomide, and Dexamethasone for Multiple Myeloma Treatment



    Watch Video

    Beth Faiman, PhD, MSN, APRN-BC, AOCN, FAAN, of the Taussig Cancer Institute, Cleveland Clinic, discusses what advanced practitioners need to know about phase III findings on subcutaneous daratumumab plus pomalidomide and dexamethasone. Compared to pomalidomide and dexamethasone alone, this combination reduced the risk of disease progression or death by 37% for patients with relapsed or refractory multiple myeloma (Abstract 412).

    2020 ASH Annual Meeting

    Sandra Kurtin, PhD, ANP-C, AOCN, on COVID-19 in Patients With Hematologic Malignancies: High False-Negative Rate With High Mortality



    Watch Video

    Sandra Kurtin, PhD, ANP-C, AOCN, of The University of Arizona Cancer Center, discusses the challenges for advanced practitioners treating patients with hematologic malignancies who are at high risk for COVID-19 infection. However, the ability to successfully detect SARS-CoV-2 in these patients remains unknown, with a strikingly high false-negative rate, and data regarding their clinical course, treatment, and outcomes is sparse (Abstract 313).

    2020 ASH Annual Meeting

    Sara Tinsley, PhD, APRN, AOCN, on CLL: Minimal Residual Disease After Venetoclax and Rituximab Therapy



    Watch Video

    Sara Tinsley, PhD, APRN, AOCN, of Moffitt Cancer Center, discusses what advanced practitioners need to know about the findings of the MURANO study, which analyzed patients with relapsed or refractory chronic lymphocytic leukemia who had enduring undetectable minimal residual disease after receiving fixed-duration treatment with venetoclax and rituximab (Abstract 125).

    2020 ASH Annual Meeting

    Beth Faiman, PhD, MSN, APRN-BC, AOCN, FAAN, on Multiple Myeloma: Patient-Reported Experiences With Belantamab Mafodotin



    Watch Video

    Beth Faiman, PhD, MSN, APRN-BC, AOCN, FAAN, of the Taussig Cancer Institute, Cleveland Clinic, discusses key insights for advanced practitioners from the DREAMM-2 study, which detailed the self-reported experiences of patients with relapsed or refractory multiple myeloma who had treatment-related side effects from belantamab mafodotin (Abstract 3248).

    2020 ASH Annual Meeting

    Sandra Kurtin, PhD, ANP-C, AOCN, on The Burkitt Lymphoma International Prognostic Index



    Watch Video

    Sandra Kurtin, PhD, ANP-C, AOCN, of The University of Arizona Cancer Center, discusses what advanced practitioners need to know about a novel prognostic index specific to Burkitt lymphoma. The index can identify patients for whom treatment may be de-escalated, as well as patients for whom currently available immunochemotherapy is appropriate (Abstract 705).

    2020 ASH Annual Meeting

    Sara Tinsley, PhD, APRN, AOCN, on B-Cell Lymphoma: Phase Ib/II Data on ViPOR for Relapsed or Refractory Disease



    Watch Video

    Sara Tinsley, PhD, APRN, AOCN, of Moffitt Cancer Center, discusses early insights for advanced practitioners on the safety, efficacy, and toxicities of the drug regimen known as ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide) for patients with relapsed or refractory B-cell lymphoma (Abstract 598).

    2020 ASH Annual Meeting

    Beth Faiman, PhD, MSN, APRN-BC, AOCN, FAAN, on Converting Minimal Residual Disease in Multiple Myeloma



    Watch Video

    Beth Faiman, PhD, MSN, APRN-BC, AOCN, FAAN, of the Taussig Cancer Institute, Cleveland Clinic, discusses what advanced practitioners need to understand about maintenance treatments with carfilzomib and lenalidomide, and conversion from minimal residual disease–positive to –negative in patients with newly diagnosed transplant-eligible multiple myeloma (Abstract 491).

    2020 ASH Annual Meeting

    Sandra Kurtin, PhD, ANP-C, AOCN, on Long-Term Side Effects Among Patients With Primary Cold Agglutinin Disease



    Watch Video

    Sandra Kurtin, PhD, ANP-C, AOCN, of The University of Arizona Cancer Center, discusses the role advanced practitioners can play in managing the unmet medical needs of patients with primary cold agglutinin disease, many of whom had severe anemia, as well as a high number of hemolysis events, requiring blood transfusions as long as 3 years after diagnosis (Abstract 151).

    2020 ASH Annual Meeting

    Sara Tinsley, PhD, APRN, AOCN, on MDS: Pevonedistat and Azacitidine for Higher-Risk Disease



    Watch Video

    Sara Tinsley, PhD, APRN, AOCN, of Moffitt Cancer Center, discusses what advanced practitioners need to understand about the findings on safety and efficacy of pevonedistat plus azacitidine vs azacitidine alone in patients with higher-risk myelodysplastic syndromes (Abstract 653).

    SOHO 2020 Annual Meeting

    Allyson Price, MPAS, PA-C, on Predicting Drug Response in Acute Lymphoblastic Leukemia



    Watch Video

    Allyson Price, MPAS, PA-C, of The University of Texas MD Anderson Cancer Center, discusses gene drug mapping, the future of precision medicine in leukemia, and the need for advanced practitioners to educate this patient population who may be new to the use of oral medications.

    SOHO 2020 Annual Meeting

    Allyson Price, MPAS, PA-C, on Immunotherapy for T-Cell ALL and T-NHL



    Watch Video

    Allyson Price, MPAS, PA-C, of The University of Texas MD Anderson Cancer Center, discusses the Keynote lecture on two complex disease states, the vital role advanced practitioners play in managing patients on CAR-T therapies, and explaining graft-vs-host disease as well as other adverse events to their patients with hematologic malignancies.

    SOHO 2020 Annual Meeting

    Allyson Price, MPAS, PA-C, on Oral HMAs for Myelodysplastic Syndrome



    Watch Video

    Allyson Price, MPAS, PA-C, of The University of Texas MD Anderson Cancer Center, discusses oral hypomethylating agents for MDS, and the implications for advanced practitioners helping patients adhere to the new regimens and maintain good quality of life.

    SOHO 2020 Annual Meeting

    Lisa Nodzon, PhD, ARNP, AOCNP, on Myelofibrosis: New Therapies in Development



    Watch Video

    Lisa Nodzon, PhD, ARNP, AOCNP, of Moffitt Cancer Center, discusses agents in phase III studies (both ongoing and planned), how the treatment landscape for myelofibrosis is changing, and what advanced practitioners need to know about managing adverse events, drug mechanisms of action, and staying up to date on the pipeline.

    SOHO 2020 Annual Meeting

    Lisa Nodzon, PhD, ARNP, AOCNP, on Multiple Myeloma: Managing Early Relapse



    Watch Video

    Lisa Nodzon, PhD, ARNP, AOCNP, of Moffitt Cancer Center, discusses new drug combinations to treat multiple myeloma, the challenges of managing relapsed and refractory disease, and the role that advanced practitioners need to play in educating patients about individualized treatments.

    SOHO 2020 Annual Meeting

    Lisa Nodzon, PhD, ARNP, AOCNP, on CLL: Measuring Residual Disease



    Watch Video

    Lisa Nodzon, PhD, ARNP, AOCNP, of Moffitt Cancer Center, discusses the progress made in treating chronic lymphocytic leukemia, the clinical implications of undetectable minimal residual disease in blood and bone marrow, and how advanced practitioners can help patients better understand their disease to weigh their treatment options.

    SOHO 2020 Annual Meeting

    Kelly Valla, PharmD, BCOP, on Relapsed or Refractory Hodgkin Lymphoma: Integrating Novel Agents



    Watch Video

    Kelly Valla, PharmD, BCOP, of Winship Cancer Institute of Emory University, discusses what advanced practitioners need to know about integrating brentuximab vedotin and PD-1 blockade earlier in the care of patients with Hodgkin lymphoma, the optimal timing of novel agents as well as new agents showing promise, and combinations that may improve outcomes.

    SOHO 2020 Annual Meeting

    Kelly Valla, PharmD, BCOP, on Peripheral T-Cell Lymphoma: Managing Relapsed Disease



    Watch Video

    Kelly Valla, PharmD, BCOP, of Winship Cancer Institute of Emory University, discusses insights for advanced practitioners on the many facets of treating peripheral T-cell lymphoma, including stem cell transplants, single agents vs combination chemotherapies, and disease targets.

    SOHO 2020 Annual Meeting

    Kelly Valla, PharmD, BCOP, on Cellular Therapy: New CAR Designs



    Watch Video

    Kelly Valla, PharmD, BCOP, of Winship Cancer Institute of Emory University, discusses next-generation CAR T cells and what advanced practitioners need to understand about enhanced cytotoxicity and increased persistence of the cells, endogenous anti-tumor immunity, and the immunosuppressive tumor microenvironment.

    2019 ASH Annual Meeting

    Sandra E. Kurtin, PhD, ANP-C, AOCN, on Multiple Myeloma in Older Patients: Isatuximab With Pomalidomide and Dexamethasone



    Watch Video

    Sandra E. Kurtin, PhD, ANP-C, AOCN, of the University of Arizona Cancer Center, discusses data from the ICARIA-MM trial that show adding isatuximab to pomalidomide and dexamethasone improved progression-free survival, overall survival, overall response rate, and very good partial response rate in older patients (65 years and older) with relapsed/refractory multiple myeloma (Abstract 1893).

    2019 ASH Annual Meeting

    Amy Pierre, ANP-BC, on CLL in Older Patients: The Alliance Trial on Ibrutinib, Obinutuzumab, and Venetoclax



    Watch Video

    Amy Pierre, ANP-BC, of Memorial Sloan Kettering Cancer Center, discusses a currently enrolling phase III trial on a new strategy to decrease exposure time to ibrutinib, which has the potential to change the standard of care for patients 70 years or older with previously untreated chronic lymphocytic leukemia (Abstract 1751).

    2019 ASH Annual Meeting

    Amy Pierre, ANP-BC, on Multiple Myeloma: Autologous Stem Cell Transplant in Older Patients



    Watch Video

    Amy Pierre, ANP-BC, of Memorial Sloan Kettering Cancer Center, discusses study findings on the decreased use of autologous stem cell transplant in older patients with multiple myeloma, despite the therapy’s significant survival benefit. The study suggests factors that make it more likely patients would forgo the treatment (Abstract 2195).

    2019 ASH Annual Meeting

    Sara Tinsley, PhD, APRN, AOCN, on MDS: MEDALIST Trial of Luspatercept to Treat Anemia



    Watch Video

    Sara Tinsley, PhD, APRN, AOCN, of Moffitt Cancer Center, discusses study findings that showed most patients with lower-risk myelodysplastic syndrome treated with luspatercept, a first-in-class erythroid maturation agent, achieved independence from red blood cell transfusions and/or hematologic improvement (Abstract 841).

    2019 ASH Annual Meeting

    Sandra E. Kurtin, PhD, ANP-C, AOCN, on Treating CLL in the Community Setting: Early Discontinuation of First-Line Ibrutinib



    Watch Video

    Sandra E. Kurtin, PhD, ANP-C, AOCN, of the University of Arizona Cancer Center, discusses the findings of a retrospective study that assessed the use of first-line ibrutinib for chronic lymphocytic leukemia in the United States. Although the agent was increasingly used in this setting, early discontinuation was more common than reported, suggesting clinical decision support tools and care delivery approaches should be explored (Abstract 797).

    2019 ASH Annual Meeting

    Sara Tinsley, PhD, APRN, AOCN, on MDS: Oral Rigosertib and Injectable Azacitidine



    Watch Video

    Sara Tinsley, PhD, APRN, AOCN, of Moffitt Cancer Center, discusses data that show rigosertib and azacitidine may provide a potential new first-line treatment for patients with high-risk myelodysplastic syndrome (Abstract 4268).

    2019 ASH Annual Meeting

    Sara Tinsley, PhD, APRN, AOCN, on CLL: Therapies After Venetoclax Discontinuation



    Watch Video

    Sara Tinsley, PhD, APRN, AOCN, of Moffitt Cancer Center, discusses study findings suggesting that BTK inhibitors in naive or previously responsive patients with chronic lymphocytic leukemia and allogeneic hematopoietic stem cell transplantation following venetoclax appear to be effective strategies with durable responses. The data indicate a number of effective regimens for patients after treatment with venetoclax, providing support for using venetoclax earlier in the course of CLL (Abstract 502).

    2019 ASH Annual Meeting

    Sandra E. Kurtin, PhD, ANP-C, AOCN, on AML in First Remission: QUAZAR Trial of Oral Azacitidine



    Watch Video

    Sandra E. Kurtin, PhD, ANP-C, AOCN, of the University of Arizona Cancer Center, discusses phase III findings on oral azacitidine, the first treatment used in the maintenance setting shown to improve both overall and disease-free survival in patients with acute myeloid leukemia that is in remission following induction chemotherapy (Abstract LBA-3).

    2019 ASH Annual Meeting

    Amy Pierre, ANP-BC, on Multiple Myeloma: CANDOR Trial of Carfilzomib, Dexamethasone, and Daratumumab



    Watch Video

    Amy Pierre, ANP-BC, of Memorial Sloan Kettering Cancer Center, discusses phase III study findings that suggest the combination of carfilzomib, dexamethasone, and daratumumab represents an efficacious new regimen for patients with relapsed or refractory disease, including those who are refractory to lenalidomide (Abstract LBA-6).

    2018 ASH Annual Meeting

    Lindsey M. Lyle, MS, PA-C, on AML: Safety Analysis of Glasdegib



    Watch Video

    Lindsey M. Lyle, MS, PA-C, of the University of Colorado Cancer Center, discusses the use of glasdegib in addition to intensive or nonintensive chemotherapy in patients with acute myeloid leukemia (Abstract 2732).

    2018 ASH Annual Meeting

    Sandra E. Kurtin, PhDc, ANP-C, AOCN, on Myeloid and Lymphoid Leukemias: A Dual Treatment Strategy



    Watch Video

    Sandra E. Kurtin, PhDc, ANP-C, AOCN, of the University of Arizona Cancer Center, discusses the dual inhibition of Bruton’s tyrosine kinase and BCL2; with the combination of venetoclax and ibrutinib, this drug combination may have broad therapeutic indications (Abstract 214).

    2018 ASH Annual Meeting

    Josh D. Epworth, MSN, ARNP, on Multiple Myeloma: Results From the Tourmaline-MM3 Trial



    Watch Video

    Josh D. Epworth, MSN, ARNP, of the University of Washington Medical Center, discusses study findings on maintenance therapy with the oral proteasome inhibitor ixazomib, which significantly prolonged progression-free survival following autologous stem cell transplantation in patients with newly diagnosed multiple myeloma (Abstract 301).

    2018 ASH Annual Meeting

    Sandra E. Kurtin, PhDc, ANP-C, AOCN, on Treatment of CLL/SLL: 7-Year Follow-up Data



    Watch Video

    Sandra E. Kurtin, PhDc, ANP-C, AOCN, of the University of Arizona Cancer Center, discusses phase Ib/II study findings on single-agent ibrutinib in the first-line and relapsed or refractory settings for chronic lymphocytic leukemia/small lymphocytic lymphoma (Abstract 3133).

    2018 ASH Annual Meeting

    Lindsey M. Lyle, MS, PA-C, on AML: Early Findings on Quizartinib and Milademetan



    Watch Video

    Lindsey M. Lyle, MS, PA-C, of the University of Colorado Cancer Center, discusses preclinical study findings on synergistic antileukemic activity with a combination of the FLT3 inhibitor quizartinib and the MDM2 inhibitor milademetan in FLT3-ITD–mutant/p53 wild-type acute myeloid leukemia models (Abstract 2720).

    2018 ASH Annual Meeting

    Josh D. Epworth, MSN, ARNP, on Multiple Myeloma: Results From the STORM Study



    Watch Video

    Josh D. Epworth, MSN, ARNP, of the University of Washington Medical Center, discusses study findings on pentarefractory multiple myeloma and the responses to oral selinexor plus low-dose dexamethasone (Abstract 598).

    2018 ASH Annual Meeting

    Sandra E. Kurtin, PhDc, ANP-C, AOCN, on CLL: Results From the MURANO Study



    Watch Video

    Sandra E. Kurtin, PhDc, ANP-C, AOCN, of the University of Arizona Cancer Center, discusses the first phase III prospective data on the impact of minimal residual disease on the long-term clinical outcomes with venetoclax plus rituximab vs bendamustine plus rituximab in chronic lymphocytic leukemia (Abstract 695).

    2018 ASH Annual Meeting

    Lindsey M. Lyle, MS, PA-C, on AML: Results From an Early Phase Dose-Escalation and Dose-Expansion Trial



    Watch Video

    Lindsey M. Lyle, MS, PA-C, of the University of Colorado Cancer Center, discusses study findings on venetoclax in combination with hypomethylating agents, which induced rapid, deep, and durable responses in patients with acute myeloid leukemia who are ineligible for intensive therapy (Abstract 285).

    2018 ASH Annual Meeting

    Josh D. Epworth, MSN, ARNP, on Multiple Myeloma: Early Results From the PAVO Trial



    Watch Video

    Josh D. Epworth, MSN, ARNP, of the University of Washington Medical Center, discusses safety and efficacy data on subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma (Abstract 1995).


Copyright © 2010-2021 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.